Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You have a proper name. Why would RGBP go ballistic on this paid report news? Yes RGBP successfully applied for and received an IND approval for HemaXellerate and then promptly did nothing to proceed to human clinical trials, even saying the tests they did weren't so conclusive...
As I recall (the years have passed you see), there was even a hospital outside the US, maybe in Panama that actually did some testing with humans and we heard no more.
RGBP does not have an approved drug or medical procedure that they can bring to market. There are clinical trials to be done first. Sure, there is the possibility that someone might license HemaXellerate knowledge, but they too would have to proceed to human clinical trials, so not likely that this article is going to ignite any rocket engines.
New shareholder here this morning. Thanks to those who have posted links to interviews and actual articles.
Pretty exciting as adult stem cells, patient's own stem cells and these peri-natal cells have so much potential for so many things. Nice to read that the founder of this company has years of experience researching this area of stem cells and this Phase I/II trial for COVID came out of a different study that already had been undertaken.
Going to be exciting following this and waiting for news at end of June. Fibonacci 61% retracement off rent high completed with this morning's drop and nice to see historical support as well in the .28 area.
Was happy my standing order was filled this morning. GLTA
Be sure to check the date of those discussions.
Then see if there has been any follow up in the years since.
"Know what you own" and "Do the DD".
Except that the board is David Koos, the company is David Koos and the shareholders he cares about are the ones who fund his income in exchange for shares given/sold to them at discounted prices.
He doesn't care about the general shareholder. He does everything for a reason and the underlying reason is total control.
Nice haul for Koos, 722M more shares sold into the recent PR tag team with ONPH puts more than $15M into Koos' pockets to keep paying himself and he can keep fishing on his boat.
Nice racket he's got going. Hard to believe it's legal, but non disclosure agreements keep a lot of people in business far longer than they should be.
Would love to know why the scientist's behind the discovery of NR2F6 and had been the public face of the company at the time was thrown out the door.
Clinical trials on $250,000. Think again. Of course, Koos and BMSN pushed HemaXellerate from IND to FDA approval for human clinical trials. I was excited at the time and thought, "This is it!". The board, like this past week was screaming "To the MOON!" and each time the price dropped, it was due to "stupid people and triggers", but eventually over time as Koos issued millions of more shares and took his salary and kicked out the scientists that had acquired the research, he did nothing with the FDA approval of HemaXellerate. To my knowledge it was never mentioned again. The Koos spun RGBP out of BMSN because of NR2F6 research and followed the same pattern. Scientist pursuing the research and making the discovery was booted out the door once patents were filed and not even given a PR that she was gone. Then from RGBP, he had to spin off 2 more of his own companies where he is the only employee, CEO, COO etc., one to link NR2F6 to the potential for animal treatments and one company for human application, so he can issue millions more shares under each...
Need we say more. Do the DD, please, everyone. NR2F6 may be a very promising component and if Eli Lilly, J&J or someone similar had stepped forward to strike a deal, I'd be all in for the future would not depend on Koos.
But who just licensed it? ONPH, which according to last filing on yahoo did have a bit of revenue back in 2013, but went dark on reporting thereafter, had no cash as of end of 2020, is issuing PRs left and right striking deals with small companies and talking about funding, but with no money, no details and no.... evidence to believe there are anything different from how Koos plays his game. Probably taking fishing trips together on Koos' yacht and came up with the current scheme.
But glad people pushed it from .000 to .06 as I was able to sell my old shares (long and strong - right) above .01 and have some change to invest elsewhere.
Ha! That's a good one. Huge vote of confidence that a stock won't go down more than 30% within a year. Great investing!
And Koos dumped them as fast as he got them because all he wants is the cash for himself. If he believed ONPH was going to produce a produce soon, (which isn't possible unless FDA rules change significantly and ONPH has no money to fund trials) why wouldn't Koos keep the shares and allow the company to build value as ONPH "skyrockets" with RGBP research and patents?
Selling ONPH shares at a discount shows Koos believes ONPH stock is going to drop and it fits the pattern of how Koos has run his multiple companies over the years. Get 3rd party people to foot his bills, sell them RGBP shares at .01/share (when RGBP was trading at .20+) so they can flip them and he gets cash. They win, he wins and shareholders that don't DT lose big time.
Most likely ONPH will be less than $10 by end of year and Koos knows it.
They sold 10,000 shares with a market value over $370,000 to a third party for $250,000 cash and this passes the smell test for everyone?
Amazing what Koos has gotten away with for so many years.
Well, .0261 best entry play right now for DT as it is support on 5 min chart.
A breach of .0261 that is more than temporary sends this back to .02 or below.
How can it possibly mean something else? To say so is deception as you cannot buy 3B O/S shares, hold them and still trade 15B shares overall.
Is there a portion of the 3B sitting in people's accounts for the long term? No doubt, but you can't have consistently 500M+ shares traded daily if people are buying and holding, unless of course, Koos is putting 500M new shares into the market daily. So, I guess you are right, it could mean something else - huge dilution never seen before, but since that has not been declared by the company, I give him the benefit of the doubt.
ONPH is signing licensing deals left and right in 2021 without any cash. RGBP now depends on ONPH for income as it has licensed its most prominent research potential to ONPH.
At the end of 2020, ONPH had no cash. Ever think as to how ONPH will be able to put that science through Phase I,II and III clinical trials for approval of something before RGBP can ever get a dime back?
And ever consider how long that is going to take.
Koos has been sitting on the research and science for so long without it going anywhere that he hasn't even bothered to file paperwork for a one employee company with the SEC.
Now, because he is going to file the reports to become current, we are to believe everything is going to become a success? Hardly. The science may be sound and I had great hopes years ago, but it's going to take a solid company with deep pockets to get it to a useful product and right now ONPH has neither the pockets nor the track record.
This is a pure DT/Momentum play. A month from now this is more likely to be .006 than .06.
As for Koos, he already has his reward, 1.7 million in stock to sell at his leisure so he can pay himself in cash and more diluted shares for the future.
So new investors beware while new DT can try their hand.
If 15 Billion shares have been traded and less than 3B have been issued (to our knowledge), that means people are not holding strong, but flipping.
This ticker will go the way of DT momentum from day to day and I predict much lower over the next 3 months once the heavy DT interest passes.
To those new to RGBP, a couple questions you need to answer before you lay your money down.
1. What is my timeframe/goal
2. What is the impetus I think will drive the price.
Don't believe the postings on this board of "to the moon", comparisons to other stocks that went up etc.
As one who has lost tens of thousands in the past on RGBP believing the hype, do your homework and learn from history.
- 1. RGBP is the not original company. The company (run by David Koos that developed HemaXellerate and DCELL etc. was BMSN (Bio-Matrix) which went to triple 000s in spite of successfully developing an IND to approval to clinical trials. No trials took place after approval. Koos created RGBP with a lower share count (at that time) to raise money and transferred the patents regarding to RGBP for the NR2F6 by an in house scientist that had dedicated her life to research because of losing her mother to cancer. Koos bought her science and issued some agreements to her for future success and then at some point, never released via PR, she is no longer employed by the company. The company at this point, with Todd Cavens leaving, is only David Koos.
2. RGBP and RGBPP went north of .50 on the expectations of NR2F6 and agreements for research with NIH.
3. As RGBP went to low pennies and then sub-pennies, Koos took RGBP's main reason of existence - NR2F6 and spun it off (licensed) to a new company he created KCL and some to Zander Therapeutics (which he also created)?
Why the need for more and more companies you should ask, especially when David Koos and maybe one other person is in charge of each? You'd have to ask him, but the obvious is selling new shares to raise money because he pays himself a salary each year upwards of 400K and if you can track down and add up all the self imposed salaries and shares of all the one man companies, who knows what it amounts to.
Did he get a good deal with ONPH - sure, 1.5M in shares with future potential royalties is a personal goldmine for him as he has gone for years just giving himself shares and selling them to live on, all while the books pile up more debt.
But that 1.5M is going to quickly absorbed when the financials come out as he will use it to pay himself off.
There is no reason that Koos filing financials is going to be reason for RGBP to "skyrocket". It will only show millions in debt.
So if you are going to invest, I hope you are a DT playing a quick in/out or a multi-year investor banking on income from ONPH. But if that is your plan, much better to invest directly in ONPH as they will reap 90-95% of income from NR2F6, while the 5%-10% to RGBP will pay for Koos' ongoing lifestyle.
RGBP licensed a good portion of its intellectual property after doing nothing with it for several years while Koos just issues millions of shares to live his life.
Looks like he got a good deal, but other than the 50,000 shares of ONPH, worth approx 1.5M (significant for RGBP which has only bled for years (I know as a shareholder back in the days of HemaXellerate development), what is the near term value or event that is going to keep the share price afloat?
$1.5M in share value, if sold, would just be used by Koos to pay himself salary, issue more stock to himself to buy at .01 or .001 so that he can sell it along the way to buy what he wants.
That's been the pattern for years. Look at all the companies and sub-companies he continues to create for legal gymnastics for his own purposes.
If ONPH actually develops the technology into useful treatments, then I agree there is potential, depending on how much debt has to be repaid etc. But over the next 12 months, what do people see being the reason RGBP goes to .50? I must be missing something.
Certainly seems like a legitimate rally over the past 2 days to a higher base. Expected much more selling pressure during the day, but seems to be holding up nicely with no panic selling or dump.
Nice.
The California case submitted as an Addendum is harder to read, but has some strong points, with the CA judge clearly siding with USRM's interpretation of the SSP Exeption and against the FDA's interpretation/application which would deny the SVP procedure solely based on the argument that the cells implanted are not the complete tissue that was removed. Judge clearly rejects that argument and states basically that the only point in dispute that could win the case for FDA is whether or not the SVF cells removed are altered before they are implanted again. USRM argues they are not altered and judge basically outlines that if USRM can prove that the SVF cells that they are extracting as part of the adipose (fat) tissue are not altered by the centrifuge/extraction process, then they win the case. At least that is my understanding of the reading.
Based on that case and outline of arguments, things look very good for USRM's outcome. The question is how long will this all take?
Another extract from USRM's appeal:
p 10 under section III
Thanks.
So far, strongest argument I've seen is on page 9 within section C.
Zues, thanks for sharing this. I hope examples like this and arguments like DragonLady's are in the briefs as today's rep by USRM lawyer was disappointing.
Hoping for the future.
I believe you are referring to the stem cell bank lawsuit here which is not directly a USRM case if my understanding is correct. The case after USRM was the appeal of clients whose stem cells were "locked" and became unaccessible to the patients because of the USRM summary judgement if I understand correctly. This case they mentioned jurisdiction etc., but that was not the case of the USRM appeal against the FDA.
In USRM's case, I didn't think the woman was all that clear or compelling in her presentation while the FDA lawyer seemed, unfortunately, very competent and knowledgeable. True, the judges asked questions and I guess the most hope was in the judge kind of cross-examining the FDA lawyer about his objections based on the claim that USRM didn't provide arguments for the active healing attributes of the cells which the judge pointed out was there.
Toss up in my opinion based on today's hearing. No clear indicator.
What I took was that FDA argues that SVP is a derivative of the fat cells and what it being put back into the person is significantly different than what is being extracted and therefore it is not excluded from FDA regulation since it doesn't come under the exemption section.
FDA example was related to skin grafts where skin is removed, cleaned, trimmed and then put back as skin whereas, in his argument, fat is removed and a cocktail of cells (not fat) is returned to the patient, thereby being a substantially "different" substance.
Seems like USRM was the previous case, no? Current case is saying they represent the people who banked their cells, no?
Thank you.
Watching Vimeo, but is the woman talking for or against USRM?
Haven't been here in a while, just caught up reading some of the legal postings. Just incredible to me to see that Berman was lying to the very end, even after the indictment, stating that he would be releasing testing data within the week as his last statement.
Doesn't seem we will be hearing from Mr. Berman anymore.
Thank you to those who did the DD to expose the ongoing lies throughout this ordeal. Sadly, I was taken in early on as I read the SEC filings thinking that it would be foolish to lie in official SEC filings over the course of the past year.
It was only after the Suspension and consistent delays and the fact that KB had a consistent pattern of contradiction or unclear PRs that I came to realize that this wasn't on the up and up. I still find it hard to believe anyone can publicly lie in his PRs and SEC filings even while under investigation and think they will get away with it.
Never too old to learn something new.
So sad.
Maybe our paths will cross on some other board in the future. Thanks to all who remained objective and shared facts.
Thanks for the overview. Most helpful and surely sounds encouraging. With 90 days after oral arguments to decide, will have to put on the patience wardrobe.
However, with no set date for a decision, will make it interesting.
Maybe, if he ever had the test data he has seemingly lied about for months. I can't believe that right after the SEC lawsuit was published he issued a PR stating that he would be continuing the business and releasing test data before the end of the week (last week). Here we are once again beyond the week and no test data whatsoever.
He keeps proving that he is a consummate liar and adding more proof to the lawsuits filed that he releases PRs that are full of misinformation and deception.
How/why he continues to do that is beyond me? If he has the test data that was "textbook results" for the XPrize competition and had submitted it a few weeks ago, how long would it take him to put it in a PR and release it? 15 mins, 30 mins max. But one wonders if the saliva based test kit is also a wishful thought only and that he never disclosed the FDA approved company's name for testing because to do so would allow potential research and affirmation that he never submitted anything to them to test.
If he had the data, nothing would prohibit him from releasing it. In fact, he has promised to do so multiple times. The fact that he has not tells the real story and hopefully he finally suffers the consequences.
But why, after all these months is there not a judgement on the Suspension Petition?
Why didn't the SEC ever rule on the Suspension suit back in July?
Had they laid all this out back in August, would have saved 4 months of waiting.
Nov 12 press release expected positive clinical trial results on Nov 13th with EUA filed within 3 weeks. That would have been around Dec 3rd.
It's Dec 10th and it appears we do not even have clinical trial data yet. And this in spite of PRs in the meantime claiming above expected test results. Hmmmm. Or did they get clinical trial data when expected that wasn't good enough and therefore are trying a new test with new settings to see if yet another combination of something might work?
When a company won't release the name of a lab or any names of it's distributors with which they are signing contracts for a product they don't yet have, what should one conclude?
On Nov 12th, KB goes out of his way to issue a PR stating that they anticipated having positive testing results the next day.
KB releases PR that he expects good news data on Friday Nov 13th.
I guess the data was so good he doesn't want to release it to investors at this time. If we don't get a PR with actual data by end of day tomorrow, then why should anyone ever believe what he releases in a PR?
For any sustained trading, DECN will need to release actual, verified test results data.
The PR muddles things because it talks about better than expected testing, but also mentions that testing will allow them to alter the meter algorithms, which means they will need more testing to have validated results with the final product to be presented to FDA for EUA, unless the initial testing is above EUA standards and they submit an initial application on the current meter and then adjust to improve the meter later for a modified submission, but given all other factors, that wouldn't seem to make much sense.
What is revealing, is that Berman mentions finalizing the meter temporarily at 1.7, which seems to indicate they have changed the meter (adjusted settings/algorithms) 7 times over the course of the development since March all the while saying that they had a test that worked and had been tested. But it seems the testing showed that the kit needed consistent adjustments/improvements over that time in order to be able to meet FDA standards.
Is the rocky road coming to a positive conclusion. Hard to say, but given that several other saliva kits are out there, DECN has a decent chance on the Saliva kit, but I wouldn't bet on the blood kit ever being approved.
Good news is that they only need one to work.
DECN is on grey sheets as a consequence of a prior SEC Trading Suspension. While they filed paperwork months ago contesting the trading suspension order, no judgement has been made.
As a grey sheet stock, there is no live Bid/Ask quote and stock is only traded by matching Bid/Asks between Investment companies is my understanding. Seems like Fidelity is not active in that realm while TD Ameritrade and others allow for buying/selling of the stock, you just can't see the bid/ask.
Very quiet on the board for a day with a PR. Berman claims they will have testing data tomorrow. Will he release it?
Afterwards, the confusion continues as he seems to contradict himself, both saying that EUA will be filed within 3 weeks and later stating that only Russian CE Mark submission is on track for 4th Qtr submittal.
If there is any hope left, it only lies in the release of actual test result data done at an official lab. We were suppose to have that on the blood test back in May, never occurred and doesn't look like it ever will.
Saliva has a better chance, but after claiming for weeks that testing of the saliva kit has been ongoing and greater than needed, no data has been released. Hard to imagine a company not wanting to release positive test data proving their product as valid, but that is where we are at.
Lastest promise is that US lab testing has begun on the saliva kit at least. If we don't get a PR with actual test data validating the saliva kit this week, that would be a highly likely sign that their saliva kit has also failed.
It's simply amazing how many times the early results exceed their expectations and how many studies have been claimed to have been performed and yet after 2 announcements of testing at FDA clinic the big news is now to have to begin to recruit donors.
Either the original expectations were very low or he keeps referring to the same work over and over again. And weeks later, still no data release.